Data Insights

BCMA-CD19 by ICell Gene Therapeutics for Systemic Lupus Erythematosus: Likelihood of Approval

BCMA-CD19 is under clinical development by ICell Gene Therapeutics and currently in Phase I for Systemic Lupus Erythematosus. According to...

Likelihood of Approval and Phase Transition Success Rate Model - BCMA-CD19 in Systemic Lupus Erythematosus

Data Insights

BCMA-CD19 by ICell Gene Therapeutics for Lupus Nephritis: Likelihood of Approval

BCMA-CD19 is under clinical development by ICell Gene Therapeutics and currently in Phase I for Lupus Nephritis. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - BCMA-CD19 in Lupus Nephritis

Data Insights

BCMA-CD19 by ICell Gene Therapeutics for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval

BCMA-CD19 is under clinical development by ICell Gene Therapeutics and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According...

Likelihood of Approval and Phase Transition Success Rate Model - BCMA-CD19 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)

Data Insights

BCMA-CD19 by ICell Gene Therapeutics for Relapsed Multiple Myeloma: Likelihood of Approval

BCMA-CD19 is under clinical development by ICell Gene Therapeutics and currently in Phase I for Relapsed Multiple Myeloma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - BCMA-CD19 in Relapsed Multiple Myeloma

Data Insights

BCMA-CD19 by ICell Gene Therapeutics for Refractory Multiple Myeloma: Likelihood of Approval

BCMA-CD19 is under clinical development by ICell Gene Therapeutics and currently in Phase I for Refractory Multiple Myeloma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - BCMA-CD19 in Refractory Multiple Myeloma

Data Insights

BCMA-CD19 by ICell Gene Therapeutics for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

BCMA-CD19 is under clinical development by ICell Gene Therapeutics and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell...

Likelihood of Approval and Phase Transition Success Rate Model - BCMA-CD19 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)